Years of extensive investigation into neurophysiology, neurochemistry, and behavioral pharmacology have produced an understanding of antipsychotic medication action that is much more refined than the original dopamine hypothesis. New perspectives offer an array of novel drugs - drugs that pose a lower risk of developing tardive dyskinesia, have fewer extrapyramidal side effects, are less sedating, and attempt to address the negative symptoms of schizophrenia. Neurotransmitter Receptors in Actions of Antipsychotic Medications presents a glimpse into the development of these breakthroughs and the field's current status in one definitive volume.
The exhaustive chapters cover the basic knowledge of schizophrenic syndromes and provide a general description of available antipsychotic drugs. Leading specialists recount the investigation into a variety of receptors in drug action and present unique topics like endogenous receptor occupation by antipsychotic drugs and regulation of brain receptors. The book also includes a survey of the future perspectives in drug design.
Each year, pharmaceutical companies invest billions of dollars in developing hundreds of medications to treat psychiatric disorders. Neurotransmitter Receptors in Actions of Antipsychotic Medications helps you study and appreciate the dynamics of these medications. You will understand the effects on receptors; predict the action, adverse side effects, and drug-drug interactions; and improve the modern antipsychotic medications that already enable people coping with schizophrenia to work, have meaningful social relationships, and live more productive lives.
"This small but very thorough textbook…an excellent contribution to the fields of psychiatry and neuroscience…a rather complicated subject is presented in a well-organized and thorough manner…a highly detailed review of antipsychotic drugs and neuroreceptors. There are many reviews of psychopharmacology, but this is one of the most specialized and exhaustive I have read. Any clinician or researcher interested in antipsychotic medications would find it a useful addition to their library."
-William Miles, M.D., Rush-Presbyterian-St. Luke's Medical Center
Schizophrenic Syndromes, Peter F. Liddle
General Overview of Antipsychotic Medications, Michael S. Lidow
Effects of Antipsychotic Drugs on Dopamine Release and Metabolism in the Central Nervous System, J. David Jentsch and Robert H. Roth
Antipsychotic Drugs, Dopamine D2, and Schizophrenia, Philip Seeman
D1 Dopamine Receptors, Schizophrenia, and Antipsychotic Medications, Akeo Kurumaji and Yoshiro Okubo
Serotonin Receptors as Targets of Antipsychotic Medications, Anissa Abi-Dargham and John Krystal
Role of Adrenergic Receptors in Effects of Antipsychotic Medications on Prefrontal Cortical Function, Amy F.T. Arnsten
Glutamate Receptors in Schizophrenia and Antipsychotic Drugs, Donald C. Goff
Antipsychotic Effects of Sigma Drugs, Ralf-Michael Friebos and Axel Steiger
GABA-ergic Drugs in Schizophrenia, Adel A. Wassef
Receptor Occupancy by Antipsychotics - Concepts and Findings, Shitij Kapur
Regulation of Neurotransmitter Receptors by Antipsychotic Medications, Lisa A. Taylor and Ian Creese
Modulation of Cellular Signaling Pathways by Antipsychotic Medications, Ashiwel Undie
The Role of Neurotransmitter Receptors in the Adverse Effects of Antipsychotic Drugs, Ronald E. See
Future Perspectives of Antipsychotic Drug Development, W. Wolfgang Fleischhacker and Josef Marksteiner